1312 - Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL

Primary Author / Presenter(s)

Tiana Huynh, MS

PhD Candidate
City of Hope - Irell and Manella Graduate School of Biological Sciences
Pasadena, California, United States

Sonia Rodriguez-Rodriguez, PhD

Staff Scientist
City of Hope
Duarte, California, United States
CR

Carly Roleder, BS

City of Hope
Duarte, California, United States
AC

Andrew Chen, MS

City of Hope
Duarte, California, United States
Vi Lam, BS

Graduate Student
COH
Duarte, California, United States
AM

Alexandra Muir, BSN

Clinical Research Nurse
City of Hope
Duarte, California, United States
GS

Geoffrey Shouse, DO

City of Hope National Medical Center
Duarte, California, United States
EL

Ernestine Lee, PhD

Nurix Therapeutics, Inc.
San Francisco, California, United States
MT

May Tan, PhD

Nurix Therapeutics, Inc.
San Francisco, California, United States
SW

Sarah Whelan, PhD

Nurix Therapeutics, Inc.
San Francisco, California, United States
Alexey V. Danilov, MD, PhD

Professor
Department of Hematology and Transplantation, City of Hope National Medical Center
Duarte, California, United States